Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again

Jul 10 2017

• By Bridget Silverman

Keeping Track Feature image

Related Content

Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns

May 25 2017

Array BioPharma’s Post-Approval Business Strategy Stymied

Mar 20 2017

Delayed Reaction: BioMarin Rises On Pegvaliase Data

Mar 23 2016

Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA

Mar 20 2017

Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing

Feb 09 2017

Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

Sep 15 2016

Related Companies

Emmaus Life Sciences, Inc.

Amgen, Inc.

Bristol Myers Squibb Company

Array BioPharma, Inc.

BioMarin Pharmaceutical Inc.

Acorda Therapeutics, Inc.

Illumina, Inc.

Novartis AG

Roche Holding AG

Additional Topics

United States Drug Review Approvals Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window